|Intellect Neurosciences shares jump 25%|
|By Staff and Wire Reports|
|Wednesday, 20 July 2011 15:54|
The science and technology platforms at the company are solid (see video below), but one big question remains: "Can ILNS maximize shareholder value while they wait for some of the big, ongoing Phase III Bapineuzemab trials play out?"
Several big pharma players have been circling around the company, looking perhaps to jump in to the race to cure Alzheimers with Dr. Daniel Chain's ANTISENILIN® monoclonal antibody technology. Invented fourteen years ago, the innovative scientific discovery targets beta amyloid, a protein widely believed to be an important contributor to the cognitive deficits seen in Alzheimer’s disease.
Importantly, ANTISENILIN® antibodies bind the major classes of beta amyloid, including soluble and plaque-bound forms, but avoid binding to the amyloid precursor protein from which beta amyloid is produced in the body. It is expected that this specificity may reduce the potential for adverse effects. Patents have been granted in Europe, Japan and several other countries with corresponding patent applications pending in the United States.
See our original coverage about the firm here:
ILNS has multiple stakes in $20 billion Alzheimer's space race Bapineuzumab and Intellect Neurosciences Attracting Attention
Exclusive: Numerous false starts by others don't discourage company's search for Alzheimer's treatment